Opiant Stock Analysis

OPNT -  USA Stock  

USD 25.88  1.12  4.15%

The newest bullish price patterns experienced by current Opiant Pharmaceuticals shareholders may encourage private investors to take a closer look at the company as it is trading at a share price of 25.88 on 47,153 in trading volume. The company executives have been very successful in rebalancing the company assets at opportune times to take advantage of market volatility in December. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.89. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Opiant Pharmaceuticals partners.
Please check Your Equity Center.

Opiant Stock Analysis 

 
Refresh
The Opiant Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Opiant Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Opiant Stock analysis module also helps to analyze the Opiant Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Opiant Stock Analysis Notes

About 30.0% of the company shares are owned by institutional investors. The book value of Opiant Pharmaceuticals was now reported as 9.1. The company next dividend is scheduled to be issued on the September 10, 2012. Opiant Pharmaceuticals had 1:100 split on the 31st of December 2014. Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people. To find out more about Opiant Pharmaceuticals contact Roger Crystal at 310 598 5410 or learn more at https://www.opiant.com.

Opiant Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Opiant Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Opiant Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Opiant Pharmaceuticals has very high historical volatility over the last 90 days
Opiant Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Opiant Pharmaceuticals currently holds about 50.33 M in cash with (1.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.66.
Latest headline from MacroaxisInsider: Acquisition by Ruth Matthew R of 12000 shares of Opiant Pharmaceuticals subject to Rule 16b-3

Opiant Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Opiant Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Opiant Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of March 2021
Next Earnings Report11th of May 2021
Next Fiscal Quarter End31st of December 2020
Next Fiscal Year End3rd of March 2021
Last Quarter Report30th of September 2020
Last Earning Announcement31st of December 2019

Opiant Largest EPS Surprises

Earnings surprises can significantly impact Opiant Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-03-04
2020-01-310.180.20.0211 
2018-11-07
2018-10-31-0.255-0.32-0.06525 
2021-05-11
2021-04-30-0.7533-0.660.093312 
View All Earnings Estimates

Opiant Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Opiant Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Opiant Pharmaceuticals backward and forwards among themselves. Opiant Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Opiant Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Marquette Asset Management LlcCommon Shares5.2 K174 K
Newbridge Financial Services Group IncCommon Shares1.9 K62 K
Lindbrook Capital LlcCommon Shares50017 K
Spire Wealth ManagementCommon Shares50017 K
National Bank Of CanadaCommon Shares100.0K
Sage Private Wealth Group LlcCommon Shares5.00.0
Wells Fargo CompanyCommon Shares247.5 K6.4 M
Note, although Opiant Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Opiant Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 122.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Opiant Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Opiant Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Opiant Profitablity

Opiant Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Opiant Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Opiant Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Opiant Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Opiant Pharmaceuticals' profitability requires more research than a typical breakdown of Opiant Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 3.58 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of 6.78 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.07.

Management Efficiency

The entity has return on total asset (ROA) of 3.22 % which means that it generated profit of $3.22 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 4.05 %, meaning that it created $4.05 on every $100 dollars invested by stockholders. Opiant Pharmaceuticals management efficiency ratios could be used to measure how well opiant pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of January, Opiant Pharmaceuticals holds the Risk Adjusted Performance of 0.0594, coefficient of variation of 1618.88, and Semi Deviation of 4.08. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Opiant Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Opiant Pharmaceuticals, which can be compared to its competitors. Please check Opiant Pharmaceuticals downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Opiant Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 25.88 per share. Given that Opiant Pharmaceuticals has jensen alpha of 0.305, we recommend you to check out Opiant Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Opiant Pharmaceuticals Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Opiant Pharmaceuticals double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Opiant Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Opiant Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Opiant Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Opiant Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David OToole over a week ago via Macroaxis 
Acquisition by David OToole of 12000 shares of Opiant Pharmaceuticals subject to Rule 16b-3
Roger Crystal over two weeks ago via Macroaxis 
Sale by Roger Crystal of 1058 shares of Opiant Pharmaceuticals
Ruth Matthew R over two weeks ago via Macroaxis 
Acquisition by Ruth Matthew R of 12000 shares of Opiant Pharmaceuticals subject to Rule 16b-3
Thomas Thomas over three months ago via Macroaxis 
Exercise or conversion by Thomas Thomas of 1834 shares of Opiant Pharmaceuticals subject to Rule 16b-3
Thomas Thomas over three months ago via Macroaxis 
Sale by Thomas Thomas of 735 shares of Opiant Pharmaceuticals
Thomas Thomas over three months ago via Macroaxis 
Exercise or conversion by Thomas Thomas of 1500 shares of Opiant Pharmaceuticals subject to Rule 16b-3
David OToole over three months ago via Macroaxis 
Purchase by David OToole of tradable shares of Opiant Pharmaceuticals
Gorman Brian over three months ago via Macroaxis 
Purchase by Gorman Brian of tradable shares of Opiant Pharmaceuticals
Craig Collard over three months ago via Macroaxis 
Purchase by Craig Collard of 9577 shares of Opiant Pharmaceuticals
Thomas Thomas over three months ago via Macroaxis 
Exercise or conversion by Thomas Thomas of 1475 shares of Opiant Pharmaceuticals subject to Rule 16b-3
Ruth Matthew R over three months ago via Macroaxis 
Purchase by Ruth Matthew R of 2000 shares of Opiant Pharmaceuticals
Michael Sinclair over three months ago via Macroaxis 
Exercise or conversion by Michael Sinclair of 50269 shares of Opiant Pharmaceuticals subject to Rule 16b-3

Opiant Pharmaceuticals Predictive Daily Indicators

Opiant Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Opiant Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Opiant Pharmaceuticals Forecast Models

Opiant Pharmaceuticals time-series forecasting models is one of many Opiant Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Opiant Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Opiant Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Opiant Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Opiant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Opiant Pharmaceuticals. By using and applying Opiant Stock analysis, traders can create a robust methodology for identifying Opiant entry and exit points for their positions.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal alcohol use disorders acute cannabinoid overdose and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Current Opiant Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Opiant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Opiant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
41.33Strong Buy3Odds
Opiant Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Opiant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Opiant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Opiant Pharmaceuticals, talking to its executives and customers, or listening to Opiant conference calls.
Opiant Analyst Advice Details

Opiant Stock Analysis Indicators

Opiant Pharmaceuticals stock analysis indicators help investors evaluate how Opiant Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Opiant Pharmaceuticals shares will generate the highest return on investment. By understating and applying Opiant Pharmaceuticals stock analysis, traders can identify Opiant Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio8.94
Fifty Two Week Low10.00
Revenue Growth79.40%
Average Daily Volume Last 10 Day61.28k
Shares Short Prior Month24.38k
Average Daily Volume In Three Month63.31k
Earnings Growth273.30%
Shares Percent Shares Out0.57%
Earnings Quarterly Growth371.30%
Gross Margins43.86%
Forward Price Earnings-7.03
Short Percent Of Float0.60%
Float Shares4.45M
Fifty Two Week High37.71
Fifty Day Average29.84
Enterprise Value To Ebitda41.85
Two Hundred Day Average20.58
Enterprise Value To Revenue2.84
Please check Your Equity Center. Note that the Opiant Pharmaceuticals information on this page should be used as a complementary analysis to other Opiant Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Opiant Stock analysis

When running Opiant Pharmaceuticals price analysis, check to measure Opiant Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opiant Pharmaceuticals is operating at the current time. Most of Opiant Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Opiant Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Opiant Pharmaceuticals' price. Additionally, you may evaluate how the addition of Opiant Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Opiant Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opiant Pharmaceuticals. If investors know Opiant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opiant Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opiant Pharmaceuticals is measured differently than its book value, which is the value of Opiant that is recorded on the company's balance sheet. Investors also form their own opinion of Opiant Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Opiant Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opiant Pharmaceuticals' market value can be influenced by many factors that don't directly affect Opiant Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opiant Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Opiant Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opiant Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.